Dublin, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Acute Lymphoblastic Leukemia" report to their offering. The entry of CAR-T therapies will offset the generic erosion of the TKI class to drive huge growth in the acute lymphoblastic leukemia (ALL) market. This report addresses the following questions: - In which treatment settings are chimeric antigen receptor T-cell (CAR-T) therapies being developed and how well are they expected to perform? - How will the current standard-of-care Gleevec fare following the launch of pipeline therapies and generic imatinib? - What effect will generics have on key branded tyrosine kinase inhibitors (TKIs)? - What pipeline therapies are in development for Ph-negative patients and how will they compete with Blincyto and Marqibo? - What are the areas of highest unmet need in the ALL market? Key Topics Covered: FORECAST: ACUTE LYMPHOBLASTIC LEUKEMIA - Blincyto (blinatumomab) - CTL0 - Gleevec (imatinib) - Iclusig (ponatinib) - inotuzumab ozogamicin - JCAR0 - Marqibo (vincristine) - Sprycel (dasatinib) - Primary Research Methodology TREATMENT: ACUTE LYMPHOBLASTIC LEUKEMIA - Disease Definition and Diagnosis - Patient Segmentation - Country Treatment Trees - Current Treatment Options - Prescribing Trends - Future Treatment EPIDEMIOLOGY: ACUTE LYMPHOBLASTIC LEUKEMIA - Disease Background - Sources and Methodology - Forecast - Epidemiologist Insight - Strengths and Limitations - Appendix MARKETED DRUGS: ACUTE LYMPHOBLASTIC LEUKEMIA - Product profile: Blincyto - Product profile: Gleevec - Product profile: Iclusig - Product profile: Sprycel PIPELINE: ACUTE LYMPHOBLASTIC LEUKEMIA - Product profile (late stage): CTL0 - Product profile (late stage): JCAR0 - Product profile (late stage): inotuzumab ozogamicin For more information visit http://www.researchandmarkets.com/research/qm2zk8/acute
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716